3/13/2026UniXell Secures FDA Clearance to Begin Clinical Testing of iPSC-Derive...

3/12/2026Hansoh Launches Phase 3 Trial of B7-H3 ADC HS-20093 With PD-L1 Therapy...

3/10/2026Novo Nordisk and United Labs Report ~20% Weight Loss With Next‑Gen Tr...

3/10/2026Ascletis Reports Positive Phase 2 Results for Monthly ASC30 Obesity Th...

3/10/2026CSPC Subsidiary Registers Phase I/II Trial for In Vivo CD19 CAR-T Ther...

3/10/2026Laekna and Eli Lilly Complete Phase 1 Study of ActRIIA Antibody LAE102...

3/10/2026Junshi Secures NMPA Acceptance for Subcutaneous Toripalimab Across 12 ...

3/9/2026Biocytogen Achieves Key Clinical Milestone as IDEAYA Initiates Phase I...

3/9/2026Regeneron Highlights Positive Chinese Phase III Data for Obesity Candi...

3/9/2026Kelun Biotech and Harbour BioMed's SKB575 Receives IND Clearance in Ch...

3/9/2026Hansoh's B7-H3 ADC Shows Promising Lung Cancer Activity in Cancer Cell...

3/9/2026Hansoh Reports Positive Phase 3 Results for Weekly GLP-1/GIP Dual Agon...

3/9/2026Merck KGaA Drops Hengrui-Licensed PARP1 Candidate After Early Clinical...

3/9/2026Abbisko's Pimicotinib Phase 3 MANEUVER Results Published in The Lancet

3/6/2026China Approves Novo's Weekly Insulin–GLP-1 Combination Therapy for Ty...

3/6/2026Abbisko Doses First Patient in Trial of KRAS G12D Inhibitor ABSK141

3/6/2026Lynk's Zemprocitinib Meets Phase III Endpoints in Atopic Dermatitis

3/6/2026Sciwind's Ecnoglutide Approved in China for Obesity

3/5/2026CMS Wins China Trial Approval for INHBE-Targeting Obesity siRNA Drug

3/4/2026CSPC's Emicizumab Injection Receives Clinical Trial Approval in China

3/4/2026Minwei Biotech's siRNA Therapy MWX401 Cleared for Clinical Trials in C...

3/4/2026Eli Lilly Advances New Oral Diabetes Therapy in China

3/3/2026LongBio Pharma's LP‑003 Shows Superior Efficacy Over Xolair in Phase ...

3/3/2026China Approves Five NMEs in February as Innovation Expands Globally

3/2/2026China Approves Jaypirca for Expanded Blood Cancer Indications

3/2/2026RemeGen NDA for RC288 Dual-Target ADC Accepted by NMPA

3/2/2026MediLink Advances HER3 ADC YL202 Into Two Phase III Trials in China

3/2/2026NMPA Approves Rovalicitinib for First-Line Myelofibrosis

3/2/2026Innovent Registers Phase I Study for FIC Dual-Payload Bispecific ADC

3/2/2026Sanofi Secures Two New China Approvals for Dupilumab

Page:1/22 Total number of articles:651: [First][<<] [1] [2] [3] [4] [5] [>>] [End]